EAM Investors LLC purchased a new stake in Evolent Health Inc (NYSE:EVH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 117,063 shares of the technology company’s stock, valued at approximately $3,325,000. EAM Investors LLC owned 0.15% of Evolent Health as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. US Bancorp DE raised its position in shares of Evolent Health by 6.1% during the third quarter. US Bancorp DE now owns 40,225 shares of the technology company’s stock worth $1,142,000 after purchasing an additional 2,301 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Evolent Health by 12.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 22,031 shares of the technology company’s stock worth $464,000 after purchasing an additional 2,459 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of Evolent Health by 16.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 21,773 shares of the technology company’s stock worth $458,000 after purchasing an additional 3,150 shares during the period. Swiss National Bank raised its position in shares of Evolent Health by 3.4% during the third quarter. Swiss National Bank now owns 100,800 shares of the technology company’s stock worth $2,863,000 after purchasing an additional 3,300 shares during the period. Finally, Oppenheimer & Co. Inc. raised its position in shares of Evolent Health by 6.2% during the third quarter. Oppenheimer & Co. Inc. now owns 59,493 shares of the technology company’s stock worth $1,689,000 after purchasing an additional 3,456 shares during the period.

Shares of NYSE EVH opened at $24.63 on Monday. The stock has a market cap of $2.03 billion, a P/E ratio of -35.19 and a beta of 1.50. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.50 and a current ratio of 2.50. Evolent Health Inc has a 1-year low of $10.85 and a 1-year high of $29.05.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, November 6th. The technology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.07. The company had revenue of $150.16 million for the quarter, compared to analysts’ expectations of $142.94 million. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. Evolent Health’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.18) EPS. As a group, equities analysts expect that Evolent Health Inc will post -0.34 earnings per share for the current year.

In related news, COO Thomas Peterson III sold 30,000 shares of the firm’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $25.00, for a total transaction of $750,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Jonathan Weinberg sold 15,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $27.12, for a total value of $406,800.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 121,805 shares of company stock worth $3,251,925. 4.82% of the stock is currently owned by insiders.

EVH has been the topic of a number of research reports. KeyCorp upped their target price on Evolent Health from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, August 20th. Leerink Swann set a $35.00 target price on Evolent Health and gave the stock a “buy” rating in a research report on Friday, October 5th. Wells Fargo & Co upped their target price on Evolent Health from $26.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 7th. Jefferies Financial Group reissued a “buy” rating and issued a $25.00 price target on shares of Evolent Health in a research report on Tuesday, August 7th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $34.00 price target on shares of Evolent Health in a research report on Wednesday, November 7th. One analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $31.73.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/11/19/eam-investors-llc-purchases-shares-of-117063-evolent-health-inc-evh.html.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Read More: No Load Funds

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.